Analysis of United States Patent 11,007,175: Antibody Binding and Therapeutic Applications
United States Patent 11,007,175, granted to Regeneron Pharmaceuticals, Inc. on May 18, 2021, discloses antibodies that bind to PCSK9 and their use in treating hypercholesterolemia and related cardiovascular conditions. The patent's claims define specific antibody sequences and their therapeutic utility, positioning it within the competitive landscape of lipid-lowering biologics.
What Does Patent 11,007,175 Claim?
The core of Patent 11,007,175 lies in its claims defining novel antibodies and their therapeutic applications.
Claim 1: Antibody Binding to PCSK9
Claim 1 is directed to an antibody, or a fragment thereof, that binds to human proprotein convertase subtilisin kexin 9 (PCSK9). The claim specifies that the antibody has particular binding characteristics, including a dissociation constant (Kd) for PCSK9 of less than or equal to 1 x 10-9 M. This high affinity binding is a critical feature, suggesting potent inhibition of PCSK9 activity. The claim further defines the antibody by its complementary determining regions (CDRs). Specifically, it requires the antibody to have a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2, a heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 3, a light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 6. These defined sequences form the antigen-binding site of the antibody, providing specificity and affinity for PCSK9.
Claim 2: Antibody with Specific Variable Regions
Claim 2 builds upon Claim 1, specifying that the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL). The claim further states that the VH region comprises the amino acid sequences set forth in SEQ ID NO: 7, and the VL region comprises the amino acid sequence set forth in SEQ ID NO: 8. These sequences define the complete variable domains of the antibody, which are responsible for antigen recognition and binding. The combination of specific CDRs and variable regions provides a detailed structural definition of the claimed antibody.
Claim 3: Antibody with Modified CDRs
Claim 3 presents a variation on the CDR sequences defined in Claim 1. It claims an antibody, or a fragment thereof, that binds to human PCSK9, where the antibody has a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, a heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 11, a light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, a light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13, and a light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14. These alternative CDR sequences suggest potential for generating antibodies with similar binding characteristics but different structural nuances, possibly impacting manufacturing or immunogenicity.
Claim 4: Antibody with Specific Variable Regions (Alternative)
Claim 4, similar to Claim 2, defines an antibody with specific variable regions. It claims an antibody, or a fragment thereof, that binds to human PCSK9, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein the VH region comprises the amino acid sequences set forth in SEQ ID NO: 15, and the VL region comprises the amino acid sequence set forth in SEQ ID NO: 16. These sequences represent another distinct antibody defined by its variable regions, offering an alternative embodiment within the patent's scope.
Claims 5-7: Antibody Isotype and Binding Affinity
Claims 5 through 7 further define characteristics of the claimed antibodies. Claim 5 asserts that the antibody is a humanized antibody. Humanization is a common technique in antibody engineering to reduce immunogenicity in humans. Claim 6 specifies that the antibody is a monoclonal antibody. Monoclonal antibodies are produced by a single clone of cells and are therefore homogeneous. Claim 7 reiterates the high binding affinity, stating that the antibody has a dissociation constant (Kd) for PCSK9 of less than or equal to 1 x 10-9 M, reinforcing the potency of the claimed agents.
Claims 8-10: Treatment of Hypercholesterolemia
Claims 8 through 10 shift focus to the therapeutic applications of the claimed antibodies. Claim 8 claims a method of treating hypercholesterolemia in a subject comprising administering an effective amount of the antibody as defined in any one of claims 1-7. This claim directly links the antibody's structure to its therapeutic benefit in lowering cholesterol. Claim 9 extends this to the treatment of a cardiovascular disease, specifying conditions such as atherosclerosis, myocardial infarction, stroke, or unstable angina. Claim 10 covers the treatment of familial hypercholesterolemia, a severe genetic form of high cholesterol. These claims highlight the broad therapeutic potential of the patented antibodies.
Claims 11-13: Pharmaceutical Compositions and Formulations
Claims 11 through 13 concern the pharmaceutical formulation of the antibodies. Claim 11 claims a pharmaceutical composition comprising the antibody as defined in any one of claims 1-7 and a pharmaceutically acceptable carrier. This claim covers the practical aspects of delivering the antibody as a drug. Claim 12 specifies a liquid formulation, and Claim 13 defines a specific concentration range for the antibody within the composition, stating it is at least 10 mg/mL. These claims address the stability, delivery, and dosage considerations for the therapeutic agents.
Claims 14-17: Nucleic Acid Sequences and Host Cells
Claims 14 through 17 move to the genetic material encoding the antibodies. Claim 14 claims an isolated nucleic acid molecule encoding the heavy chain variable region as set forth in SEQ ID NO: 7 and the light chain variable region as set forth in SEQ ID NO: 8. Claim 15 claims a nucleic acid molecule encoding the heavy chain as set forth in SEQ ID NO: 17 and the light chain as set forth in SEQ ID NO: 18. Claims 16 and 17 claim host cells comprising these nucleic acid molecules, enabling the production of the antibodies.
What is the Patent Landscape for PCSK9 Inhibitors?
The patent landscape for PCSK9 inhibitors is characterized by significant innovation, extensive patent filings, and intense competition, primarily driven by the success of monoclonal antibodies targeting PCSK9.
Key Players and Patented Technologies
Major pharmaceutical companies have heavily invested in developing and patenting PCSK9 inhibitors. Regeneron Pharmaceuticals, Inc. is a prominent player with its antibody, Praluent (alirocumab), which is covered by patents originating from the technology disclosed in U.S. Patent 11,007,175 and related applications. Amgen, Inc. has developed Repatha (evolocumab), another highly successful PCSK9 inhibitor. The patent portfolios for these companies include broad claims covering antibody sequences, therapeutic uses, and methods of treatment.
The patent landscape includes:
- Antibody Sequences: Patents claim specific amino acid sequences for variable regions, CDRs, and entire antibody chains of PCSK9 inhibitors. These claims are crucial for defining the core intellectual property of a biologic. For example, U.S. Patent 11,007,175 claims specific CDRs and variable region sequences for its PCSK9-binding antibodies.
- Therapeutic Uses: Patents cover the use of PCSK9 inhibitors for treating hypercholesterolemia, reducing cardiovascular risk, and managing specific genetic lipid disorders like familial hypercholesterolemia.
- Formulations and Delivery Methods: Patents also protect specific pharmaceutical compositions, including liquid formulations and dosage strengths, as well as methods of administration.
- Methods of Treatment: Claims often focus on methods of treating patients with elevated LDL-C levels or those at high risk of cardiovascular events.
Competitive Dynamics and Litigation
The PCSK9 inhibitor market is highly competitive, with Repatha and Praluent being the leading biologics. This competition has led to extensive patent litigation. Companies actively seek to invalidate competitor patents or establish infringement to protect their market share. For instance, disputes have arisen concerning the patentability of antibody sequences and the scope of claims related to therapeutic efficacy.
The development of biosimilars is also a factor in the long-term patent strategy. As patents expire or are successfully challenged, the market opens to biosimilar versions, requiring companies to have robust patent protection throughout the product lifecycle.
Patent Expirations and Future Outlook
Many of the foundational patents for PCSK9 antibodies are expected to expire in the coming years. This will create opportunities for biosimilar manufacturers. However, companies often strategically file continuation applications and pursue new patentable inventions related to next-generation PCSK9 inhibitors, different delivery mechanisms, or combination therapies to extend their intellectual property protection. The ongoing research into PCSK9 targets not only LDL-C reduction but also potential effects on other biological pathways, which could lead to new patentable discoveries.
What is the Scope of U.S. Patent 11,007,175?
U.S. Patent 11,007,175 has a well-defined scope centered on specific antibodies targeting PCSK9, their underlying genetic sequences, and their therapeutic applications.
Antibody Specificity and Affinity
The patent's primary scope is defined by the specific amino acid sequences of the antibodies, particularly their CDRs and variable regions. The claims delineate distinct antibody structures, such as those defined by SEQ ID NOs: 1-8 and SEQ ID NOs: 9-16. A critical aspect of the scope is the asserted binding affinity to human PCSK9, with a dissociation constant (Kd) of less than or equal to 1 x 10-9 M. This high affinity is a key functional characteristic that underpins the therapeutic utility described in the patent.
Therapeutic Applications
The scope extends to the therapeutic use of these antibodies. Specifically, the patent claims methods of treating hypercholesterolemia, cardiovascular diseases (including atherosclerosis, myocardial infarction, stroke, and unstable angina), and familial hypercholesterolemia. This broad therapeutic scope signifies the patent's intent to cover the use of these agents across a range of lipid-related conditions.
Pharmaceutical Compositions and Manufacturing
The patent also encompasses pharmaceutical compositions containing the claimed antibodies, including liquid formulations and specific concentration ranges (at least 10 mg/mL). Furthermore, it covers the underlying nucleic acid sequences that encode these antibodies and the host cells engineered to produce them. This provides protection over the manufacturing process and the genetic basis of the therapeutic agents.
Exclusivity and Market Protection
The scope of U.S. Patent 11,007,175, by defining specific antibody structures and their applications, grants Regeneron Pharmaceuticals, Inc. exclusive rights to make, use, sell, offer for sale, and import these particular PCSK9-binding antibodies within the United States for the duration of the patent term. This exclusivity is critical for recouping research and development investments and establishing market position. The patent's specific sequence claims can be highly effective in preventing competitors from developing antibodies that are structurally identical or highly similar.
Key Takeaways
- Specific Antibody Sequences: Patent 11,007,175 claims antibodies defined by precise heavy and light chain variable region and CDR amino acid sequences.
- High Affinity Binding: A key characteristic is the claimed high dissociation constant (Kd) of ≤ 1 x 10-9 M for binding to human PCSK9, indicating potent inhibition.
- Broad Therapeutic Utility: The patent covers the use of these antibodies for treating hypercholesterolemia, cardiovascular diseases, and familial hypercholesterolemia.
- Pharmaceutical Formulation: Claims extend to pharmaceutical compositions, including liquid formulations at specified concentrations.
- Manufacturing Protections: The patent includes claims on nucleic acid sequences encoding the antibodies and host cells used in their production.
- Competitive Landscape: The patent operates within a highly competitive PCSK9 inhibitor market, characterized by extensive patenting and litigation among major pharmaceutical firms.
Frequently Asked Questions
-
What are the specific SEQ ID numbers mentioned in U.S. Patent 11,007,175 and what do they represent?
U.S. Patent 11,007,175 references multiple SEQ ID numbers, each corresponding to specific amino acid sequences of antibody components. For example, SEQ ID NOs: 1-6 define the CDRs of one embodiment of the claimed antibody, while SEQ ID NOs: 7 and 8 define the variable heavy and light chain regions, respectively. Other SEQ ID numbers, such as 9-18, define alternative CDR and variable region sequences for different embodiments of the claimed antibodies. These sequences are the precise building blocks of the PCSK9-binding antibodies.
-
What is the significance of the stated dissociation constant (Kd) of ≤ 1 x 10-9 M in the patent claims?
A dissociation constant (Kd) of less than or equal to 1 x 10-9 M signifies a very high affinity binding interaction between the antibody and its target, human PCSK9. In practical terms, this means the antibody binds tightly to PCSK9, suggesting it can effectively neutralize PCSK9's function at lower concentrations and with greater stability. This high affinity is crucial for the therapeutic efficacy of PCSK9 inhibitors in lowering LDL cholesterol.
-
Beyond hypercholesterolemia, what other specific cardiovascular conditions are covered by the patent's therapeutic claims?
The patent claims methods for treating cardiovascular diseases, which are explicitly enumerated to include atherosclerosis, myocardial infarction, stroke, and unstable angina. This indicates a broad therapeutic scope intended to address the downstream clinical consequences of elevated LDL cholesterol that the PCSK9 inhibitors are designed to mitigate.
-
Does U.S. Patent 11,007,175 prevent the development of biosimilars for PCSK9 inhibitors?
U.S. Patent 11,007,175 specifically protects the particular antibody sequences and their uses as described within its claims. While it provides strong protection for the claimed inventions for its duration, it does not inherently prevent the development of biosimilars for other PCSK9 inhibitors or for the same drug after the patent's expiry. Biosimilar development typically focuses on demonstrating high similarity to an already approved biologic product and navigates existing patent landscapes, which can include challenging patent validity or avoiding patented elements.
-
What role do the nucleic acid sequence claims (Claims 14-17) play in the patent's overall protection?
The claims directed to isolated nucleic acid molecules encoding the antibody's heavy and light chains, and to host cells containing these nucleic acids, provide protection over the genetic material and the means of producing the antibody. This strengthens the patent's exclusionary power by covering the fundamental biological blueprints and manufacturing platforms for the PCSK9-binding antibodies, thereby preventing unauthorized replication or production of the antibodies.
Citations
[1] Regeneron Pharmaceuticals, Inc. (2021, May 18). Antibodies that bind to PCSK9 and methods of use. U.S. Patent No. 11,007,175. Retrieved from USPTO Patent Full-Text and Image Database.
